Keybank National Association OH Raises Stake in AbbVie Inc. $ABBV

Keybank National Association OH lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 0.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,053,057 shares of the company’s stock after purchasing an additional 8,229 shares during the quarter. AbbVie comprises approximately 0.9% of Keybank National Association OH’s holdings, making the stock its 22nd largest holding. Keybank National Association OH’s holdings in AbbVie were worth $240,613,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ABBV. Brighton Jones LLC grew its holdings in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC grew its holdings in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares during the period. Schnieders Capital Management LLC. grew its holdings in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares during the period. Ieq Capital LLC grew its holdings in shares of AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after purchasing an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC grew its holdings in shares of AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after purchasing an additional 612,702 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.2%

Shares of ABBV opened at $197.84 on Wednesday. The business’s 50 day moving average is $215.29 and its two-hundred day moving average is $221.79. AbbVie Inc. has a 52-week low of $176.57 and a 52-week high of $244.81. The firm has a market cap of $349.81 billion, a price-to-earnings ratio of 83.83, a PEG ratio of 0.71 and a beta of 0.38.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the company posted $2.16 EPS. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts expect that AbbVie Inc. will post 14.21 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.5%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Piper Sandler decreased their price target on AbbVie from $299.00 to $294.00 and set an “overweight” rating for the company in a report on Thursday, April 23rd. Finally, Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 11th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.19.

Insider Activity at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie filed a U.S. FDA application to expand RINVOQ (upadacitinib) to treat adults and adolescents with severe alopecia areata — a new label that could add incremental sales if approved. AbbVie Submits Application to FDA for Upadacitinib (RINVOQ) for Adults and Adolescents with Severe Alopecia Areata
• Positive Sentiment: AbbVie submitted an FDA application to expand SKYRIZI (risankizumab‑rzaa) subcutaneous induction for Crohn’s disease — another label expansion that, if approved, supports Skyrizi’s growth profile. AbbVie Submits Regulatory Application to FDA for SKYRIZI (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn’s Disease
• Positive Sentiment: Topline SELECT‑SWITCH Phase 3b/4 data show RINVOQ (upadacitinib) beat HUMIRA on the primary endpoint in RA patients who failed a TNF inhibitor — supportive clinical data for market share gains. RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study
• Positive Sentiment: AbbVie secured an option/warrant arrangement with Kestrel (KRAS inhibitor) and may acquire the company for up to $1.45B as Kestrel advances its pan‑KRAS program — strengthens oncology pipeline exposure. AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B
• Positive Sentiment: Kestrel announced first patient dosed in its Phase 1 pan‑KRAS trial; the program is tied to AbbVie’s option — clinical progress that could trigger future deal milestones. Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051
• Positive Sentiment: EvolveImmune announced a preclinical milestone in a collaboration with AbbVie, triggering an $18M payment — validates external partnership model and de‑risks some immuno‑oncology work. EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
• Neutral Sentiment: AbbVie is due to report Q1 earnings tomorrow; previews expect Skyrizi and RINVOQ to drive recovery — near‑term volatility possible around results. AbbVie (ABBV) To Report Earnings Tomorrow: Here Is What To Expect
• Neutral Sentiment: Market pieces are re‑assessing AbbVie’s valuation after recent share softness vs longer‑term gains — useful context but not an immediate catalyst. Assessing AbbVie (ABBV) Valuation After Recent Share Price Softness And Long Term Gains
• Negative Sentiment: A small biotech’s experimental psoriasis drug (Oruka) produced ~two‑thirds complete clearance in trials — a direct competitive threat to AbbVie’s large psoriasis franchise (~$18B) and a key reason for investor nerves. How A Small Biotech Name Just Rattled AbbVie’s $18 Billion Franchise
• Negative Sentiment: The FDA issued a Complete Response Letter (CRL) for AbbVie’s trenibotulinumtoxinE biologics license application — a regulatory setback that delays or jeopardizes a product launch. AbbVie Inc. (ABBV) Receives CRL from the FDA About the Biologics License Application for trenibotulinumtoxinE

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.